Baxter International Inc. ($BAX) Stock Forecast: Up 5.3% Today

What is Baxter International Inc.?

Baxter International Inc. (BAX) is a global healthcare company specializing in treatments for various medical conditions, including hemophilia, kidney disease, and immune disorders. The company is recognized for its advanced medical solutions and dedication to patient well-being.

Why is Baxter International Inc. going up?

BAX stock is up 5.3% on Jun 4, 2026 14:21

• Baxter's stock witnessed a bullish movement recently, driven by internal factors like executive stock transactions and equity grants. These actions signal confidence and stability within the company's leadership.
• The launch of the IV Verify Line Labeling System highlights Baxter's ongoing focus on innovation and patient safety, which could attract investor attention and contribute to stock price growth.
• The growth of the refurbished medical equipment industry, with industry leaders like GE HealthCare and Siemens Healthineers, might have positively influenced Baxter's stock performance as part of the broader healthcare sector trend. Investors may see Baxter as well-prepared to capitalize on industry growth and technological advancements.

BAX Price Chart

BAX Technical Analysis

BAX News

Baxter (BAX) executive forfeits 321 shares to cover RSU tax withholding

Baxter International executive James Teaff forfeited 321 shares of common stock on June 2, 2026, at $18.68 per share to cover tax withholding obligations arising from vested restricted stock units granted on June 2, 2025. This was a routine, non-discretionary transaction intended to satisfy taxes on equity compensation, and not an open-market sale. After the forfeiture, Teaff directly holds 31,063 shares of Baxter common stock, including those in the company's Employee Stock Plan.

https://www.stocktitan.net/sec-filings/BAX/form-4-baxter-international-inc-insider-trading-activity-2edcf6f66775.html

Baxter (BAX) interim CFO Anita Zielinski receives 13,426-share equity grant

Baxter International Inc.'s interim CFO, Anita A. Zielinski, was granted 13,426 shares of common stock as a restricted stock unit (RSU) award. This grant, valued at $0.00 per share, is a one-time special award tied to her additional duties as interim CFO and will vest on the third anniversary of the grant date. Following this transaction, Zielinski directly holds 59,714 shares of Baxter common stock, including automatic reinvestment of dividends.

https://www.stocktitan.net/sec-filings/BAX/form-4-baxter-international-inc-insider-trading-activity-17e46a14792a.html

Baxter (BAX) surgery president forfeits shares to cover RSU tax bill

Steven P. Wallace, Baxter International's President of Advanced Surgery, forfeited 153 shares of common stock on June 2, 2026, to cover tax withholding obligations. This forfeiture was triggered by the vesting of restricted stock units originally granted on June 2, 2025. After this transaction, Wallace directly holds 70,128 shares of Baxter common stock, indicating this was a routine tax handling event rather than an open-market sale.

https://www.stocktitan.net/sec-filings/BAX/form-4-baxter-international-inc-insider-trading-activity-666aa090bea5.html

Baxter Introduces IV Verify Line Labeling System

Baxter International Inc. has launched the IV Verify Line Labeling System, an automated solution developed through an exclusive distribution agreement with Vigilant Software. This system aims to improve patient safety and nursing efficiency by replacing traditional handwritten IV labels with clear, standardized, and color-coded adhesive labels. It helps clinicians quickly identify medications, administration times, and tubing change times, thereby reducing medication errors and streamlining workflow in healthcare settings.

https://www.mpo-mag.com/breaking-news/baxter-introduces-iv-verify-line-labeling-system/

Top 10 Companies Driving Growth in Refurbished Medical Equipment Industry

The refurbished medical equipment industry is experiencing significant growth, projected to reach USD 35.74 billion by 2034 with a CAGR of 10.8%. This growth is driven by the modernization of healthcare, demand for cost-effective solutions, and technological innovations like AI-assisted models and remote diagnostics. Key players such as GE HealthCare, Siemens Healthineers, and Koninklijke Philips N.V. are leading this sector by offering sustainable, high-quality, and regulated refurbished devices.

https://www.fortunebusinessinsights.com/blog/top-10-refurbished-medical-equipment-companies-11223

Trending Today

NASDAQ-100 ($NDX) Index Forecast: Down 0.6% Today

Medtronic plc. ($MDT) Stock Forecast: Up 5.0% Today

SL Green Realty Corp ($SLG) Stock Forecast: Up 5.1% Today

SBA Communications Corporation ($SBAC) Stock Forecast: Up 5.0% Today

Arista Networks Inc. ($ANET) Stock Forecast: Down 5.1% Today

Virgin Galactic Holdings Inc ($SPCE) Stock Forecast: Up 12.6% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 8.9% Today

Centene Corporation ($CNC) Stock Forecast: Up 5.6% Today

Crown Castle International Corp. (REIT) ($CCI) Stock Forecast: Up 5.2% Today

UnitedHealth Group Incorporated (DE) ($UNH) Stock Forecast: Up 5.2% Today

Baxter International Inc. Price History

01.03.2026 - BAX Stock was up 5.1%

• The bullish movement in Baxter International Inc. (BAX) stock can be attributed to the launch of its IV Verify Line Labeling System, showcasing the company's commitment to improving patient safety and nurse productivity in clinical settings.
• The positive market response indicates investor confidence in Baxter's strategic developments and potential for revenue growth in the global intravenous solutions market.
• Despite some recent declines in stock performance, this innovative product launch has reignited investor interest and positioned Baxter International for further market expansion and success in the healthcare industry.

30.03.2026 - BAX Stock was up 5.4%

• Despite reporting a Q1 loss, Baxter International Inc. (BAX) experienced a strong bullish movement in the stock market.
• The bullish trend could be attributed to the company's ability to surpass Wall Street expectations in terms of adjusted earnings per share and revenue.
• Investors may be optimistic about Baxter's strategic initiatives post the Kidney Care divestiture and the company's reiterated full-year guidance, which could indicate stability and growth potential.
• The positive market response to Baxter's financial results suggests that investors are focusing more on the company's long-term outlook and operational performance rather than short-term losses.

30.03.2026 - BAX Stock was up 3.2%

• Despite posting a Q1 loss, Baxter International Inc. experienced a strong bullish movement in the stock market.
• The bullish trend could be attributed to the company's robust sales performance, with revenue exceeding expectations and demonstrating a 5% year-over-year increase.
• Investors may have been encouraged by Baxter's resilience in the face of challenges like higher costs and tariffs, as well as the company's reaffirmation of its full-year guidance and strategic initiatives.
• The market reaction, with the stock soaring 7.6%, indicates investor confidence in Baxter's ability to navigate the medtech market landscape and drive long-term growth.

26.02.2026 - BAX Stock was up 5.1%

• BAX stock rose by 2.39% to $17.12, surpassing its competitors for the third consecutive day.
• The positive market sentiment, reflected in the S&P 500 Index and Dow Jones Industrial Average increases, likely contributed to this rise.
• Investor optimism about Baxter's product portfolio and growth opportunities, especially in healthcare, may have fuelled its strong performance.
• Although therapy animal program news is beneficial for healthcare, it had minimal direct impact on BAX's stock movement.

27.02.2026 - BAX Stock was down 5.2%

• Baxter International Inc. (BAX) experienced a substantial 2.63% drop to $16.67, halting a previous positive trend in concurrence with the broader bearish market conditions.
• Following a downgrade in the outlook by S&P, citing concerns about leverage and free cash flow, Bank of America maintained a Hold rating on BAX.
• Investor interest heightened due to a recent CFO change at Baxter International, with the stock trading below its estimated fair value, hinting at potential undervaluation.
• Despite The Vanguard Group reporting 0% ownership post an internal rearrangement, which had no substantial impact on the stock's performance, as it was merely an administrative adjustment.

27.02.2026 - BAX Stock was down 6.4%

• Bank of America maintained a Hold rating on Baxter International (BAX) with a $24 price target, while S&P downgraded the stock's outlook to Negative, causing a bearish movement.
• The recent CFO transition at Baxter International (BAX) has raised concerns about its valuation, as the stock is trading below the fair value, suggesting potential undervaluation.
• Baxter International Inc. (BAX) stock performed poorly compared to its competitors on a negative trading day, contributing to the overall bearish trend.
• Despite the announcement of Baxter's online-only annual meeting and the focus on convenience and cost-effectiveness, it did not prevent the decline in the stock amidst negative market sentiment.

14.03.2026 - BAX Stock was up 5.6%

• Baxter International Inc. showcased its latest innovations, including the AAT XR spine surgical table and Dynamo Series smart stretcher, at the AORN Global Surgical Conference & Expo. These new products aim to improve efficiency, support safer patient care, and address common challenges faced by healthcare teams in surgical settings.
• The company's stock outperformed competitors on a strong trading day, rising by 2.80%. This positive market reaction could be attributed to investor optimism surrounding Baxter's commitment to evolving its portfolio through collaboration with healthcare professionals and its focus on enhancing efficiency and patient care.
• The emphasis on Baxter's new surgical and patient support products, designed to enhance efficiency, streamline workflows, and improve patient care in operating rooms, likely contributed to the bullish movement in the stock price.
• Overall, the market responded positively to Baxter's innovative product showcase at the conference, reflecting investor confidence in the company's ability to drive growth and address the evolving needs of the healthcare industry.

29.03.2026 - BAX Stock was down 5.6%

• Baxter International Inc. (BAX) stock declined by 2.97% on Tuesday, performing below market indices.
• Analysts predict stagnant year-on-year revenue for Q1 earnings, indicating a slowdown compared to previous periods.
• Challenges in product categories aimed at hospitals and unfavorable comparisons are expected to have a negative impact on revenue.
• BlackRock Inc.'s 6.4% ownership filing in Baxter International Inc. may have affected market sentiment, contributing to the bearish trend.

29.03.2026 - BAX Stock was down 5.3%

• Baxter International Inc. (BAX) stock experienced a strong bearish movement, falling 2.97% to $17.94, underperforming the market indices.
• The stock's underperformance could be attributed to the broader market decline, as both the S&P 500 Index and Dow Jones Industrial Average also saw decreases.
• Despite the company's positive Q1 earnings report and potential for recovery, the market pressures and the stock closing significantly below its 52-week high might have contributed to the bearish movement.
• The filing by BlackRock Inc. showing a 6.4% ownership of Baxter International Inc. shares could also be a factor influencing market sentiment, although not directly causing the bearish movement.

31.02.2026 - BAX Stock was up 5.0%

• Baxter International experienced a bullish movement following the successful launch of its IV Verify Line Labeling System, designed to enhance IV medication accuracy and minimize errors in clinical environments.
• Market response has been positive towards Baxter's efforts to reinforce its infusion therapy ecosystem, as demonstrated by its partnership with Vigilant Software to address compliance issues and streamline nurse operations.
• Despite recent stock declines, investor outlook appears bullish on Baxter's ability to leverage the growing intravenous solutions market with this new technology, contributing to today's positive performance.
• The introduction of this cutting-edge system underscores Baxter's dedication to innovation and patient safety, potentially increasing investor trust and driving the stock's upward momentum amid a day of mixed trading in the broader market.

17.03.2026 - BAX Stock was up 8.2%

• Baxter International Inc. stock witnessed a notable surge today, possibly due to its defensive growth profile and focus on essential hospital products.
• The company's strong position in the healthcare sector, emphasizing its hospital supply advantage, could have attracted investors seeking stability in uncertain economic times.
• With the increasing demand for crucial medical supplies, Baxter International Inc.'s stock performance may be benefiting from the rising need for its products, particularly in the expanding Blood And Blood Components Market.
• The generally positive market outlook towards healthcare stocks, alongside Baxter International Inc.'s robust business model and market positioning, likely played a role in its bullish movement today.

04.05.2026 - BAX Stock was up 5.3%

• Baxter's stock witnessed a bullish movement recently, driven by internal factors like executive stock transactions and equity grants. These actions signal confidence and stability within the company's leadership.
• The launch of the IV Verify Line Labeling System highlights Baxter's ongoing focus on innovation and patient safety, which could attract investor attention and contribute to stock price growth.
• The growth of the refurbished medical equipment industry, with industry leaders like GE HealthCare and Siemens Healthineers, might have positively influenced Baxter's stock performance as part of the broader healthcare sector trend. Investors may see Baxter as well-prepared to capitalize on industry growth and technological advancements.